Author

L. Schild

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

B. Koopmans· 3 shared J. J. Molenaar· 3 shared J. Koster· 2 shared S. R. van Hooff· 2 shared A. H. W. Essing· 1 shared E. M. Dolman· 1 shared F. Westermann· 1 shared H. N. Caron· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. Koopmans

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Two opposing gene expression patterns within ATRX aberrant neuroblastoma

M. R. van Gerven, L. Schild, J. van Arkel, B. Koopmans, L. A. Broeils, L. A. M. Meijs, R. van Oosterhout, M. M. van Noesel, J. Koster, S. R. van Hooff, J. J. Molenaar, M. van den Boogaard

The paper identifies two opposing gene expression patterns in ATRX-aberrant neuroblastoma models, suggesting distinct molecular mechanisms and treatment implications.

bioRxiv · Oct 25, 2022 · PreprintCancer Biology

Loss of p16INK4a in neuroblastoma cells induces shift to an immature state with mesenchymal characteristics and increases sensitivity to EGFR inhibitors

N. A. Schubert, S. R. van Hooff, L. Schild, K. Ober, M. Hortensius, K. van den Handel, A. H. W. Essing, B. Koopmans, M. Boeije, N. Proost, M. van de Ven, S. Jansky, S. A. Stainczyk, U. H. Toprak, F. Westermann, , M. L. van den Boogaard

bioRxiv · Oct 27, 2021 · PreprintCancer Biology

MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma

T. F. Eleveld, L. Vernooij, L. Schild, B. Koopmans, L. K. Alles, M. E. Ebus, P. G. van Sluis, H. N. Caron, J. Koster, R. Versteeg, E. M. Dolman, J. J. Molenaar

The paper identifies MEK inhibition combined with BCL2 family inhibitors as a potent treatment for RAS-MAPK mutated neuroblastoma by stabilizing Bim and increasing sensitivity to Bcl2 inhibitors.

bioRxiv · Feb 12, 2020 · PreprintCancer Biology